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Abstract
Objective: Rare variants in certain transcription factors involved in cardiac development cause Mendelian forms of
congenital heart disease. The purpose of this study was to systematically assess the frequency of rare transcription factor
variants in sporadic patients with the cardiac outflow tract malformation tetralogy of Fallot (TOF).
Methods and Results: We sequenced the coding, 59UTR, and 39UTR regions of twelve transcription factor genes implicated
in cardiac outflow tract development (NKX2.5, GATA4, ISL1, TBX20, MEF2C, BOP/SMYD1, HAND2, FOXC1, FOXC2, FOXH, FOXA2
and TBX1) in 93 non-syndromic, non-Mendelian TOF cases. We also analysed Illumina Human 660W-Quad SNP Array data for
copy number variants in these genes; none were detected. Four of the rare variants detected have previously been shown
to affect transactivation in in vitro reporter assays: FOXC1 p.P297S, FOXC2 p.Q444R, FOXH1 p.S113T and TBX1 p.P43_G61del
PPPPRYDPCAAAAPGAPGP. Two further rare variants, HAND2 p.A25_A26insAA and FOXC1 p.G378_G380delGGG,
A488_491delAAAA, affected transactivation in in vitro reporter assays. Each of these six functionally significant variants
was present in a single patient in the heterozygous state; each of the four for which parental samples were available were
maternally inherited. Thus in the 93 TOF cases we identified six functionally significant mutations in the secondary heart
field transcriptional network.
Significance: This study indicates that rare genetic variants in the secondary heart field transcriptional network with
functional effects on protein function occur in 3–13% of patients with TOF. This is the first report of a functionally significant
HAND2 mutation in a patient with congenital heart disease.
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Introduction
Tetralogy of Fallot (TOF), the commonest cyanotic form of
congenital heart disease (CHD), comprises ventricular septal
defect, deviation of the outlet septum leading to over-riding of
the aortic valve and right ventricular outflow tract obstruction, and
right ventricular hypertrophy. Whilst approximately 20% of cases
occur in the context of chromosomal abnormalities or recognised
syndromes, the majority are isolated anomalies and family studies
in these cases are consistent with a complex genetic model. A
number of studies have tested the role of individual genes in
patients with TOF; for example, rare variants in NKX2.5 have
been associated with the condition [1] but few have tested multiple
genes in the same patients though this will change with the
increasing application of exome sequencing [2]. When parental
samples have been available an almost invariable finding has been
that changes have been inherited from an unaffected parent, thus
it has often been difficult to demonstrate that the variants
identified contributed to the phenotype. However, transmission
of alleles contributing to but not on their own sufficient to cause a
phenotype is entirely consistent with the complex genetic model.
We selected twelve transcription factors that function in the
same network for study, Figure 1 [3]. Among the genes in this
network, GATA4, NKX2.5 and TBX20 mutations have all been
reported in familial CHD, typically septal defects [MIM 607941;
MIM 108900; MIM 611363] [2,4–7]. Although mutations in
TBX1 have been reported [8,9,], TBX1 hemizygosity in the
context of chromosome 22q11 deletion syndrome is much more
common and an important cause of CHD including TOF.
Mutations in other genes in this transcription network cause
disorders in which non-cardiac malformations predominate, but in
which CHD may also be a feature. FOXC1 mutations cause
Axenfeld Rieger syndrome type 3 (ARS) [MIM: RIEG3 602482],
which is characterised by anterior chamber eye malformations and
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increased risk of glaucoma though CHD occurs in a significant
proportion of affected individuals [10,11]. FOXC2 mutations
cause lymphoedema distachiasis syndrome [MIM 153400]; CHD
is present in around ten percent of affected individuals [12]. By
contrast, MEF2C hemizygosity or mutation causes severe mental
retardation [13] [MIM 613443]; no patients with MEF2C
mutations have been reported as having CHD. The remaining
genes in the network shown in Figure 1 are not, as yet, associated
with Mendelian disorders. The contribution of rare variants in
these genes, considered together, in non-Mendelian, non-syndro-
mic CHD is as yet unclear. We screened a panel of ninety three
patients with TOF for mutations and assessed the functional
impact of the variants we discovered. We observed rare functional
and presumably deleterious variants in 6/93 patients, suggesting
that such variants, while individually rare, are relatively common
in TOF and may contribute importantly to disease susceptibility.
Materials and Methods
Ethical statement
Ethical approval was granted to the study by the NHS
Multicentre Research Ethics Committee for the Northern Region
(REC reference number E4/Q0902/33) and written informed
consent was obtained from all participants (or their parents, if the
patient was a child too young to themselves consent). We were not
granted Ethics approval to undertake parental echocardiograms.
Study population
Probands affected with Tetralogy of Fallot (TOF) were recruited
from four UK cardiology centres: Leeds General Infirmary; Alder
Hey Children’s Hospital, Liverpool; Bristol Royal Hospital for
Children and Newcastle upon Tyne NHS Hospitals Foundation
Trust. Clinical records were reviewed before recruitment and
probands with known chromosomal abnormalities, other recog-
nised syndromes, learning difficulties, or known maternal exposure
to significant teratogens during pregnancy were excluded. In
addition, proband samples were screened for chromosome
22q11.2 deletion by multiplex ligation-dependent probe amplifi-
cation (MRC-Holland, Amsterdam) to exclude DiGeorge/Velo-
cardiofacial syndrome. All probands were of Caucasian origin and
the control population consisted of ethnically-matched individuals
with no history of CHD. Blood or saliva samples were collected for
DNA extraction from 58 proband-parent trios, 18 proband-
mother pairs, 2 proband-father pairs and 15 probands alone.
Exon Re-sequencing
Eleven genes, namely NKX2.5, GATA4, ISL1, TBX20,
MEF2C, BOP/SMYD1, HAND2, FOXC1, FOXC2, FOXH1
and FOXA2 were re-sequenced in 93 TOF patients. TBX1 had
already been re-sequenced in the same group of patients [14].
Primers were designed based on Ensembl transcription boundaries
so that amplicons would cover 59 and 39 untranslated, coding and
splice boundary regions of all isoforms of the genes of interest and
bidirectional sequencing was undertaken by standard Sanger
sequencing. The Staden Package of programs (http://staden.
sourceforge.net/) was used to analyse the sequence traces.
Variants observed in the TOF panel that were not present in
dbSNP build 131 were screened by genotyping in a cohort of 500
unrelated people free of CHD. This was carried out by the most
appropriate method in each case, including iPLEX MALDI-TOF
assays (Sequenom), custom Allelic Discrimination Taqman probes
(Applied Biosciences), capillary electrophoresis of fluorescent-
labelled amplicons, primer specific PCR and/or RFLP assays.
Copy number variation
Ninety (of 93 screened) TOF subjects, along with 737 controls
(unaffected members of TOF families), were typed on Illumina
Human 660W-Quad SNP Array (Illumina Inc., San Diego, CA,
USA). Genotyping was performed at Centre National de
Ge´notypage (Evry Cedex, France). After initial QC analyses, 28
individuals were excluded due to low calls or high heterozygosity.
The remaining 86 TOF individuals and 713 controls were
Figure 1. Secondary heart field transcriptional network. Solid lines indicate demonstrated direct in vivo activation. Dotted lines indicate
genetic data or in vitro activation (reprinted by permission from original copyright Macmillan Publishers Ltd: Nature Genetics Reviews 6 (11): 826–835
2005). http://www.ncbi.nlm.nih.gov/pubmed/16304598.
doi:10.1371/journal.pone.0095453.g001
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subjected for further analyses of copy number variation as
described previously [15]. Dosage analysis for NKX2.5, GATA4,
ISL1, TBX20, MEF2C, BOP/SMYD1, HAND2, FOXH1,
FOXA2, FOXC1, FOXC2 and TBX1 was carried out using
Ensembl transcription boundaries of all available isoforms that
were retrieved at hg18 build at UCSC Table Browser as of
October 11, 2010. All co-ordinates were mapped to NCBI build
36.1 (hg18). Coverage for the genes analysed in the Illumina
660W-Quad SNP Array is given in table S1.
Expression constructs and luciferase assays
Full-length human cDNA expression constructs HAND2-
pcDNA3.1, HNF-3b-pcDNA3.1 (FOXA2), pcDNA4/HIS-
MAXvB-FOXC1, and mouse pcDNA3.1-TBX20 have been
described previously [16–19]. The non-synonymous rare variants
found in TOF patients in the coding regions of transcription
factors HAND2, FOXA2, FOXC1, and TBX20 were introduced
by site-directed mutagenesis (QuickChange, Stratagene) into the
respective expression constructs. A luciferase reporter driven by an
appropriate promoter or binding region was used in combination
with each expression construct in order to measure the transcrip-
tional activity of the expressed wild type (or mutant) transcription
factors. Cells were seeded in 12-well plates for 24 hours before
being transfected with empty vector, wild type or mutant
expression construct along with the respective reporter construct.
In addition, a GFP expression vector or Renilla luciferase vector
was co-transfected into the cells as a control for transfection
efficiency. Cells were incubated at 37uC and harvested 24 or
48 hours after transfection. Luciferase activity of the lysates was
measured using the Dual-Luciferase Reporter Assay System
(Promega) according to the manufacturer’s instructions (but
without addition of the Stop and Glow reagent in cases where
GFP was used as control). Transfection details of each specific
assay are given in table S2. GFP fluorescence was measured on the
Fluoroskan Ascent FL (ThermoScientific) using excitation at
485 nm and emission at 538 nm. Luciferase data was normalised
to the transfection control (GFP fluorescence or Renilla luciferase
readings). For each construct, a minimum of three independent
experiments were each performed in triplicate. Results are
expressed as mean 6 standard deviation. Statistical significance
was determined by two sample t-test assuming equal variance.
Minigene constructs and RT-PCR
The rare synonymous variants found in the GATA4 and ISL1
genes were studied by minigene assays (exon trapping) to establish
whether they impaired correct splicing. The remaining rare
synonymous variants were not studied as they were located in
exons not subjected to splicing. Using primers incorporating
EcoRI restriction sites, each exon of interest plus 400 bp of its
flanking intronic region was amplified from patient DNA and
cloned into the MfeI site of construct pXJ41 [20]. pXJ41 contains
a CMV promoter and two constitutive small b-globin exons. The
wild type (or mutant) amplicon containing the relevant exon and
its flanking intronic region was inserted between the b-globin
exons. For each assay, 1 mg of the wild type (or variant) minigene
construct was incubated in Optimem (Invitrogen) with 1.5 ml of
Fugene HD (Roche) and transfected (in duplicate) into 70%
confluent HEK293 cells seeded in 6-well plates and grown in
DMEM +10% FBS for 24 hr. After 24 hours cells were harvested
and RNA was extracted using Trizol, the RNA was DNAse
treated to avoid amplification of the remaining transfected plasmid
and then reverse transcribed using primers complementary to the
beta-globin exons (forward 59-GCTCCGGATCGATCCTGA-
GAACT-39 and reverse 59-GTAACCATTATAAGCTG-39). The
relative size of mutant and wild type amplicons were visualised
under UV light after 2% agarose gel electrophoresis.
Results
Sequencing and copy number analysis of secondary
heart field genes in TOF patients
TBX1 sequencing in this cohort has been reported previously
[14]. Sequencing the coding, untranslated and exon boundary
regions of the remaining 11 transcription factor genes in 93 TOF
patients identified 40 variants that were not present in dbSNP
build 131. Six variants not present in dbSNP build 131 were
present in the control population with a frequency of .1% (table
S3).The frequency of the remaining 34 changes in the Exome
Variant Server, NHLBI GO Exome Sequencing Project (ESP),
Seattle, WA (URL: http://evs.gs.washington.edu/EVS/) [August
2013], 1000 Genomes (http://browser.1000genomes.org) and in
our own controls are shown in Table 1. Half (17/34) of the rare
variants were in coding regions, 14 were in 39 and 59 untranslated
regions and 3 were intronic. Of the 17 coding region variants, 3
were synonymous changes and 14 were non-synonymous changes;
10 resulting in amino acid substitutions and 4 resulting in in-frame
insertions or deletions. No copy number variants removing a gene
or part of a gene were detected.
Four non-synonymous variants were found in FOXC1 and
FOXA2, two in FOXC2, and single non-synonymous variants were
found in GATA4, TBX20, HAND2 and FOXH1. Each variant
was present in a single patient apart from GATA4 c.1037C.T
(p.A346V) and c.*1012G.C; and FOXH1 c.-333T.C that were
found in two patients each, and the intronic GATA4 c.909+25G.
A that was found in 3 patients. We included the TBX1 re-
sequencing information for these patients [14] when considering
the hypothesis that changes in more than one gene in the
pathway may predispose to TOF. Most patients presented a single
variant, however two variants were found in three patients. The
first patient carried both GATA4 c.*886G.A and TBX1
c.*1074G.A (both maternal in origin); the second carried
BOP/SMYD1 c.*271C.T and TBX1 c.129_185del, p.P43_
G61del PPPPRYDPCAAAAPGAPGP (inherited from the father
and mother, respectively) and the third carried both FOXC1
c.1132_1140del, p.G378_G380delGGG and c.1462_1473del,
p.A488_491delAAAA (both on the maternally derived allele).
Three variants were found in two patients. The first carried BOP/
SMYD1 c.*2435C.T (paternal), HAND2 c.75_76insGCCGCC,
p.A25_A26insAA (maternal) and FOXA2 c.280G.C, p.A94P
(maternal). The second patient carried GATA4 c.*979G.C
(maternal) FOXA2 c.872C.T, p.A291V (paternal) and TBX1
c.*11C.T (maternal). All variants were heterozygous. Of the
28/34 rare variants for which parent of origin could be
determined 20 were inherited from the mother and 8 from the
father; parental samples were not available to test whether the
remaining six rare variants were inherited or had occurred de
novo. No novel changes were detected in NKX2.5 or MEF2C.
Functional investigation
Four of the rare variants detected have previously been shown
to affect transactivation in in vitro reporter assays: FOXC1
p.P297S, FOXC2 p.Q444R, FOXH1 p.S113T and TBX1
p.P43_G61del PPPPRYDPCAAAAPGAPGP. Six variants
(HAND2 p.A25_A26insAA, FOXA2 p.A94P, p.I189F and
p.Y445C, and FOXC1 p.G378_G380delGGG and p.A488_
491delAAA) were not present in 1000 control chromosomes,
NHLBI Exome Sequencing Project or 1000 Genomes. For the
missense changes, in silico tools predicted FOXA2 p.A94P,
Cardiac Transcription Factor Variants in TOF
PLOS ONE | www.plosone.org 3 August 2014 | Volume 9 | Issue 8 | e95453
T
a
b
le
1
.
R
ar
e
va
ri
an
ts
fo
u
n
d
in
th
e
9
3
T
e
tr
al
o
g
y
o
f
Fa
llo
t
p
at
ie
n
ts
.
G
e
n
e
L
o
ca
ti
o
n
B
a
se
a
a
ch
a
n
g
e
Id
In
h
.
5
0
0
co
n
tr
o
ls
(%
)
N
H
L
B
I
(%
)
1
0
0
0
g
(%
)
d
b
S
N
P
1
3
7
FO
X
A
2
in
tr
o
n
1
c.
-2
+4
_
+1
7
d
e
l
n
/a
5
8
—
—
—
—
—
e
x
o
n
3
c.
2
8
0
G
.
C
p
.A
9
4
P
2
8
M
—
—
—
rs
2
0
1
3
5
0
6
4
6
c.
5
6
5
A
.
T
p
.I1
8
9
F
4
0
P
—
—
—
—
c.
8
7
2
C
.
T
p
.A
2
9
1
V
7
3
P
0
.2
—
—
rs
2
0
0
4
5
9
0
0
3
c.
1
3
3
4
A
.
G
p
.Y
4
4
5
C
3
5
—
—
—
—
—
c.
*4
7
1
d
u
p
A
n
/a
(3
’U
T
R
)
7
1
M
—
—
—
—
FO
X
C
1
e
x
o
n
1
c.
8
1
_
8
9
d
e
l
G
C
G
G
C
G
G
C
C
p
.A
2
8
_
A
3
0
d
e
lA
A
A
3
1
3
M
0
.3
—
—
—
c.
8
8
9
C
.
T
p
.P
2
9
7
S
6
6
M
—
—
1
.7
rs
7
9
6
9
1
9
4
6
c.
1
1
3
2
_
1
1
4
0
d
e
l
p
.G
3
7
8
_
G
3
8
0
d
e
lG
G
G
2
2
M
—
—
—
—
c.
1
4
6
2
_
1
4
7
3
d
e
l
p
.A
4
8
8
_
4
9
1
d
e
lA
A
A
A
2
2
M
—
—
—
—
FO
X
C
2
e
x
o
n
1
c.
5
8
3
C
.
G
p
.P
1
9
5
A
7
8
P
0
.2
—
—
rs
2
0
0
7
5
1
9
4
1
c.
1
3
3
1
A
.
G
p
.Q
4
4
4
R
3
4
—
0
.2
0
.1
4
—
rs
1
4
7
2
5
8
4
5
3
FO
X
H
1
5
’U
T
R
c.
-5
4
3
C
.
T
n
/a
6
0
M
0
.4
—
—
c.
-3
3
3
T
.
C
n
/a
7
6
P
0
.6
—
—
rs
1
4
7
2
7
6
1
6
2
3
4
2
—
c.
-1
3
6
d
e
lC
n
/a
6
9
P
0
.2
—
—
—
c.
-7
6
_
8
8
d
e
l
T
C
A
G
G
T
C
C
C
G
G
C
C
n
/a
2
9
M
—
—
—
—
e
x
o
n
3
c.
3
3
8
G
.
C
p
.S
1
1
3
T
5
0
0
—
0
.8
0
.6
6
0
.2
rs
1
4
4
8
3
0
7
4
0
G
A
T
A
4
e
x
o
n
2
c.
6
9
9
G
.
A
p
.T
2
3
3
T
3
2
3
—
—
0
.3
0
.1
rs
5
5
7
8
8
3
8
7
in
tr
o
n
3
-4
c.
9
0
9
+2
5
G
.
A
n
/a
5
0
7
—
0
.9
0
.7
2
0
.0
0
3
rs
1
4
7
8
6
0
1
7
4
5
0
9
—
3
3
1
M
e
x
o
n
5
c.
1
0
3
7
C
.
T
p
.A
3
4
6
V
5
9
—
0
.4
0
.3
1
0
.1
3
rs
1
1
5
3
7
2
5
9
5
6
1
M
e
x
o
n
6
c.
1
1
6
4
G
.
A
p
.A
3
8
8
A
3
1
5
M
—
0
.0
3
—
-
rs
5
5
9
6
8
1
7
8
c.
*8
8
6
G
.
A
n
/a
(3
’U
T
R
)
3
1
9
M
—
—
0
.4
rs
1
4
6
3
0
4
3
4
1
c.
*9
7
9
G
.
C
n
/a
(3
’U
T
R
)
7
3
M
0
.1
—
0
.1
3
rs
1
8
2
3
6
5
3
1
3
c.
*1
0
1
2
G
.
C
n
/a
(3
’U
T
R
)
6
7
—
0
.1
—
0
.1
3
rs
1
3
9
5
6
6
3
9
0
7
4
—
H
A
N
D
2
e
x
o
n
1
c.
7
5
_
7
6
in
sG
C
C
G
C
C
p
.A
2
5
_
A
2
6
in
sA
A
2
8
M
—
—
—
—
IS
L1
in
tr
o
n
2
-3
c.
2
1
9
-3
C
.
T
n
/a
5
1
4
M
—
—
—
—
3
’U
T
R
c.
*2
4
5
A
.
G
n
/a
4
4
M
—
—
—
—
c.
*6
5
1
A
.
G
n
/a
3
9
M
0
.5
—
—
—
B
O
P
/S
M
Y
D
3
’U
T
R
c.
*1
4
0
T
.
C
n
/a
3
0
P
—
—
—
—
c.
*2
7
1
C
.
T
n
/a
3
3
0
P
0
.1
—
—
—
Cardiac Transcription Factor Variants in TOF
PLOS ONE | www.plosone.org 4 August 2014 | Volume 9 | Issue 8 | e95453
p.I189F and p.Y445C to be damaging (with PolyPhen scores of
0.918, 1 and 1 respectively). Based on this, the transcriptional
activities of HAND2 p.A25_A26insAA, FOXA2 p.A94P, p.I189F
and p.Y445C, and the compound FOXC1 p.G378_G380delGGG
and p.A488_491delAAAA were compared to the activities of their
respective wild type transcription factors. In addition, we studied
the transcriptional activity of TBX20 p.I122V as variation of the
neighbouring amino acid results in gain of function [7] although it
was predicted by Polyphen to be benign (0.352).
HAND2. Transient expression of HAND2 in HEK293 cells
results in up-regulation of the ANP-luciferase reporter [16].
Insertion of two alanines in a tract of 12 alanines (p.A25_A26in-
sAA) reduced the up-regulation to 80% of the wild type levels
(p = 0.02, Figure 2, panel a).
FOXA2. Transient expression of FOXA2 in HUH7 cells
results in down-regulation of the OATP8-luciferase reporter [17].
None of the three non-synonymous FOXA2 variants investigated
(p.A94P, p.I189F, and p.Y445C) affected transcriptional activity as
measured by this luciferase reporter assay (data not shown).
TBX20. Transient expression of TBX20 and constitutively
active ALK3 in NIH3T3 cells results in down-regulation of a
Tbx2-Luc reporter [19]. There was no difference in the down-
regulation observed between wild-type TBX20 and the p.I122V
variant (data not shown).
FOXC1. Transient expression of FOXC1 in COS7 cells
results in up-regulation of the 6xBS-luciferase reporter [18].
Deletion of either three glycines or four alanines independently
had no effect on FOXC1 transcriptional activity (data not shown).
As the GGGdel and the AAAAdel occurred on the same allele an
expression construct carrying both variants was also tested. This
variant increased transcriptional activity compared to the wild
type protein (p = 0.003). (Figure 2, panel b).
Investigation of splicing
The mutant minigene constructs for ISL1 c.219-3C.T and
GATA4 c.699G.A p.T233T produced an RNA profile identical
to the wild type construct indicating that splicing was not affected
by these genetic changes (data not shown).
Discussion
Nineteen coding region variants that occurred in less than 1% of
control chromosomes were identified in 93 TOF cases in the
secondary heart field transcription network genes, eleven tran-
scription factors studied here and TBX1 analysed in the same
cases previously [14]. These variants comprised eleven missense,
one in-frame insertion, four in-frame deletions (one complex) and
three synonymous variants; no truncating variants were found. All
bar one, GATA4 p.A346V, was found in a single patient and each
patient had only one of these variants. In all cases for which
parental samples were available the rare variants had been
inherited.
The functional effect of the novel variants that were absent from
the controls was assessed by reporter assays. In the assay systems
we utilised, the HAND2 insertion and the FOXC1 compound
deletion were functionally significant. Four further rare variants,
each present in one of the TOF cases, had been observed and
studied previously and found to alter transactivation capacity:
FOXC1 p.P297S, FOXC2 p.Q444R, FOXH1 p.S113T and
TBX1 p.P43_G61del PPPPRYDPCAAAAPGAPGP [21–23]
[14]. Finally, TBX20 p.I122V was also studied as a change in
the adjacent amino acid (TBX20 p.I121M), identified in a patient
with an ostium secundum atrial septal defect, increased transacti-
vation [7].
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We found that a variant present in one patient resulting in the
insertion of two alanines in a tract of 12 alanines (p.A25_A26in-
sAA) in HAND2 decreased transcriptional activity. Expansions of
polyalanine tracts are a well-recognised cause of disease [24]. In
the majority of these disorders the polyalanine tracts occur in
genes encoding transcription factors. The length of the polyalanine
tract is generally in the order of 10A–20A and typical expansions
range from five to fourteen alanines but expansions by two alanine
residues have been reported to be sufficient to cause disease
[25,26]. In addition to tetralogy of Fallot this patient had an absent
thyroid gland (Table 2). A deletion in the orthologous zebrafish
gene causes thyroid agenesis and an insertion in the zebrafish gene
causes reduction in the size of the thyroid gland. The similarity of
this additional phenotype between the zebrafish model and the
patient provide further support for the pathogenicity of this
HAND2 mutation [27]. There have been no previous reports of
HAND2 mutations associated with other human phenotypes and
there is only one report on HAND2 analysis in patients with CHD
[28]. This study detected one missense mutation (p.P11R) in two
TOF patients that was not present in 250 ethnically matched
controls, no functional data was presented. A number of patients
have been reported with duplications and deletions of chromo-
Table 2. Clinical information of TOF patients with rare, functionally significant variants.
Patient Id Gene Change Phenotype
22 FOXC1 p.378GGGdel, p. 488AAAAdel Tetralogy of Fallot with bicuspid pulmonary valve, subvalvar and valvar
stenosis, hypoplasia of left pulmonary artery at insertion of ductus
arteriosus, confluent branch pulmonary arteries, left aortic arch.
28 HAND2 p.A25_A26insAA Tetralogy of Fallot with pulmonary atresia and major aortopulmonary
collateral arteries, right aortic arch, small atrial septal defect, small central
pulmonary arteries, absent thyroid gland.
34 FOXC2 p.Q444R Tetralogy of Fallot with moderate valvar pulmonary stenosis and mild
subvalvar pulmonary stenosis, confluent branch pulmonary arteries, pyloric
stenosis.
66 FOXC1 p.P297S Tetralogy of Fallot with moderate to severe subvalvar pulmonary stenosis,
confluent branch pulmonary arteries, right aortic arch, patent foramen
ovale.
330 TBX1 p.P43_G61del PPPPRYDPCAAAAPGAPGP Tetralogy of Fallot with a dysplastic pulmonary valve, patent foramen ovale
and right aortic arch, severe valvar and supravalvar pulmonary stenosis,
confluent branch pulmonary arteries.
500 FOXH1 p.S113T Tetralogy of Fallot with severe valvar and subvalvar pulmonary stenosis,
right aortic arch, confluent branch pulmonary arteries, ligamentum
arteriosum.
doi:10.1371/journal.pone.0095453.t002
Figure 2. Transcriptional activity of wild type and rare non-synonymous variants of transcription factors HAND2 and FOXC1. a) The
HAND2 p.A25_A26insAA variant showed significantly reduced activation of the ANP reporter construct; b) The FOXC1 p.378GGGdel+488AAAAdel
variant showed significantly increased activation of the 6xBS reporter construct. All assays were repeated at least three times, each time in triplicate
and standard deviations are shown.
doi:10.1371/journal.pone.0095453.g002
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some 4q33, the chromosomal region containing HAND2. Patients
with both duplications and deletions have a high incidence of
congenital heart defects including tetralogy of Fallot consistent
with dosage sensitivity for this gene in human cardiogenesis but all
duplications and deletions have affected multiple genes [29,30].
Three cases in the group had a FOXC1 coding change, these
were a deletion of three alanine residues that was also present in
three of the controls, a missense change, FOXC1 p.P297S, and
non-contiguous deletion of three glycines and four alanine
residues. None of these changes were in the forkhead domain.
FOXC1 has been intensively studied in Axenfeld Rieger syndrome
(ARS) patients. FOXC1 p.P297S has been reported in two
patients with this condition and reported to decrease transcrip-
tional activity to 75% of normal levels [21]. Neither the affected
child in this study nor the parent from whom the variant was
inherited had a known eye problem. Furthermore this change has
now been reported in the 1000 genome project suggesting that if it
is a cause of ARS it is not fully penetrant. The majority of FOXC1
mutations in ARS localise to the forkhead domain and decrease
transcriptional activity [31]. In contrast combined deletion of the
three glycines and 4 alanines increased transcriptional activity in
the reporter assay suggesting that increased activity of FOXC1
may play a role in CHD aetiology. Importantly, however,
inheritance from an unaffected parent emphasises the likely
requirement for additional genetic and/or environmental factors
for CHD to occur. It is also noteworthy that functional testing
showed no effect of each variant comprising the maternal
haplotype individually, but a significant increase in transcriptional
activity when a construct incorporating both variants was used.
This illustrates the potential importance of incorporating multiple
variants on a haplotype for functional testing, where these are
encountered.
The purpose of this study was to assess the contribution of rare
variants in the secondary heart field transcriptional network to
TOF. We identified novel changes in HAND2 and FOXC1 that
affected reporter transactivation and found changes in FOXH1,
FOXC1 and FOXC2 that had previously been shown by others to
have affect transactivation capacity. Interestingly these latter
changes did not meet the criteria we had selected for functional
analysis as they were present in controls. We had previously
studied TBX1 in the same 93 patients and detected a functionally
significant in-frame deletion [14]. Had our criteria been less
stringent functional assays would have been undertaken for an
additional three changes in GATA4, FOXC1 and FOXC2
respectively. Although the three FOXA2 changes were predicted
to be damaging by PolyPhen no change was observed in the
readout of the functional assays, nor for TBX20 p.I122V. More
detailed phenotypic information for the six patients with
functionally significant changes is shown in Table 2. It is
noteworthy that four of the six patients had a right sided aortic
arch, a feature seen in approximately a quarter of TOF patients
[32].
Our study has shown that rare coding variants in genes in a
network playing a central role in the development of right-sided
cardiac structures and the outflow tract occur relatively frequently
in sporadic, non-syndromic tetralogy of Fallot; the 95% confidence
interval of the proportion we observed (6 functionally significant
variants/93 cases) is between 3 and 13%. This suggests that a
network-wise comparison of variant burden, albeit in much larger
numbers of patients and controls, could demonstrate a statistically
significant excess of variants among the TOF patients. Difficulties
with such an approach would include the precise a priori
definition of the gene network, and our observation that among
the rare variants we detected, not all exhibited functional
significance in the assays we adopted. In this regard, it is possible
that the in vitro assays we chose do not faithfully reflect the effect
of the investigated variants on embryonic development; moreover,
although the functional differences we observed were reproducible
and statistically significant, they were of relatively small magni-
tude. We did not detect examples where functional assays
supported di- or polygenic inheritance, though further study in
larger patient groups is needed to obtain adequate power to
address combinations of changes.
Supporting Information
Table S1 Coverage for the genes analysed in the
Illumina 660W-Quad SNP Array.
(XLSX)
Table S2 Transfection details of luciferase assays.
(XLSX)
Table S3 Variants found with a frequency of.1% in the
control population.
(XLSX)
Acknowledgments
The principal acknowledgement is to the patients and families who
participated in this study. We thank study nurses Kath Ashcroft, Linda
Sneddon, Claire Roberts, Helen Walker and Jayne Peters, and Rafiqul
Hussein for technical support. We also acknowledge Prof. Anthony Firulli,
Prof. Michael Walter, Prof. Richard Harvey, Prof. Andreas Kispert and
Dr. Rhonda Bassel-Duby, who generously gave plasmids used in functional
assays.
Author Contributions
Conceived and designed the experiments: AT HRG JO AGS BDK JAG.
Performed the experiments: AT HRG EG RS DH TJR CJ. Analyzed the
data: AT HRG EG RS DLB DH. Contributed reagents/materials/analysis
tools: JJE AGS JO. Wrote the paper: AT JAG BDK.
References
1. Goldmuntz E, Geiger E, Benson DW (2001) NKX2.5 mutations in patients with
tetralogy of fallot. Circulation 104: 2565–2568.
2. Granados-Riveron JT, Pope M, Bu’lock FA, Thornborough C, Eason J, et al.
(2012) Combined mutation screening of NKX2-5, GATA4, and TBX5 in
congenital heart disease: multiple heterozygosity and novel mutations. Congenit
Heart Dis 7: 151–159.
3. Buckingham M, Meilhac S, Zaffran S (2005) Building the mammalian heart
from two sources of myocardial cells. Nat Rev Genet 6: 826–835.
4. Garg V, Kathiriya IS, Barnes R, Schluterman MK, King IN, et al. (2003)
GATA4 mutations cause human congenital heart defects and reveal an
interaction with TBX5. Nature 424: 443–447.
5. Hirayama-Yamada K, Kamisago M, Akimoto K, Aotsuka H, Nakamura Y,
et al. (2005) Phenotypes with GATA4 or NKX2.5 mutations in familial atrial
septal defect. Am J Med Genet A 135: 47–52.
6. Kirk EP, Sunde M, Costa MW, Rankin SA, Wolstein O, et al. (2007) Mutations
in cardiac T-box factor gene TBX20 are associated with diverse cardiac
pathologies, including defects of septation and valvulogenesis and cardiomyop-
athy. Am J Hum Genet 81: 280–291.
7. Posch MG, Gramlich M, Sunde M, Schmitt KR, Lee SH, et al. (2010) A gain-of-
function TBX20 mutation causes congenital atrial septal defects, patent foramen
ovale and cardiac valve defects. J Med Genet 47: 230–235.
8. Yagi H, Furutani Y, Hamada H, Sasaki T, Asakawa S, et al. (2003) Role of
TBX1 in human del22q11.2 syndrome. Lancet 362: 1366–1373.
9. Zweier C, Sticht H, Aydin-Yaylagul I, Campbell CE, Rauch A (2007) Human
TBX1 missense mutations cause gain of function resulting in the same
phenotype as 22q11.2 deletions. Am J Hum Genet 80: 510–517.
10. Cunningham ET Jr, Eliott D, Miller NR, Maumenee IH, Green WR (1998)
Familial Axenfeld-Rieger anomaly, atrial septal defect, and sensorineural
hearing loss: a possible new genetic syndrome. Arch Ophthalmol 116: 78–82.
Cardiac Transcription Factor Variants in TOF
PLOS ONE | www.plosone.org 7 August 2014 | Volume 9 | Issue 8 | e95453
11. Grosso S, Farnetani MA, Berardi R, Vivarelli R, Vanni M, et al. (2002) Familial
Axenfeld-Rieger anomaly, cardiac malformations, and sensorineural hearing
loss: a provisionally unique genetic syndrome? Am J Med Genet 111: 182–186.
12. Brice G, Mansour S, Bell R, Collin JR, Child AH, et al. (2002) Analysis of the
phenotypic abnormalities in lymphoedema-distichiasis syndrome in 74 patients
with FOXC2 mutations or linkage to 16q24. J Med Genet 39: 478–483.
13. Zweier M, Gregor A, Zweier C, Engels H, Sticht H, et al. (2010) Mutations in
MEF2C from the 5q14.3q15 microdeletion syndrome region are a frequent
cause of severe mental retardation and diminish MECP2 and CDKL5
expression. Hum Mutat 31: 722–733.
14. Griffin HR, Topf A, Glen E, Zweier C, Stuart AG, et al. (2010) Systematic
survey of variants in TBX1 in non-syndromic tetralogy of Fallot identifies a
novel 57 base pair deletion that reduces transcriptional activity but finds no
evidence for association with common variants. Heart 96: 1651–1655.
15. Soemedi R, Wilson IJ, Bentham J, Darlay R, Topf A, et al. (2012) Contribution
of global rare copy-number variants to the risk of sporadic congenital heart
disease. Am J Hum Genet 91: 489–501.
16. Thattaliyath BD, Firulli BA, Firulli AB (2002) The basic-helix-loop-helix
transcription factor HAND2 directly regulates transcription of the atrial
naturetic peptide gene. J Mol Cell Cardiol 34: 1335–1344.
17. Vavricka SR, Jung D, Fried M, Grutzner U, Meier PJ, et al. (2004) The human
organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally
repressed by hepatocyte nuclear factor 3beta in hepatocellular carcinoma.
J Hepatol 40: 212–218.
18. Saleem RA, Banerjee-Basu S, Berry FB, Baxevanis AD, Walter MA (2001)
Analyses of the effects that disease-causing missense mutations have on the
structure and function of the winged-helix protein FOXC1. Am J Hum Genet
68: 627–641.
19. Singh R, Horsthuis T, Farin HF, Grieskamp T, Norden J, et al. (2009) Tbx20
interacts with smads to confine tbx2 expression to the atrioventricular canal.
Circ Res 105: 442–452.
20. Bourgeois CF, Popielarz M, Hildwein G, Stevenin J (1999) Identification of a
bidirectional splicing enhancer: differential involvement of SR proteins in 5’ or
3’ splice site activation. Mol Cell Biol 19: 7347–7356.
21. Fetterman CD, Mirzayans F, Walter MA (2009) Characterization of a novel
FOXC1 mutation, P297S, identified in two individuals with anterior segment
dysgenesis. Clin Genet 76: 296–299.
22. Roessler E, Ouspenskaia MV, Karkera JD, Velez JI, Kantipong A, et al. (2008)
Reduced NODAL signaling strength via mutation of several pathway members
including FOXH1 is linked to human heart defects and holoprosencephaly.
Am J Hum Genet 83: 18–29.
23. van Steensel MA, Damstra RJ, Heitink MV, Bladergroen RS, Veraart J, et al.
(2009) Novel missense mutations in the FOXC2 gene alter transcriptional
activity. Hum Mutat 30: E1002–1009.
24. Albrecht A, Mundlos S (2005) The other trinucleotide repeat: polyalanine
expansion disorders. Curr Opin Genet Dev 15: 285–293.
25. Bienvenu T, Poirier K, Friocourt G, Bahi N, Beaumont D, et al. (2002) ARX, a
novel Prd-class-homeobox gene highly expressed in the telencephalon, is
mutated in X-linked mental retardation. Hum Mol Genet 11: 981–991.
26. Brais B, Bouchard JP, Xie YG, Rochefort DL, Chretien N, et al. (1998) Short
GCG expansions in the PABP2 gene cause oculopharyngeal muscular
dystrophy. Nat Genet 18: 164–167.
27. Wendl T, Adzic D, Schoenebeck JJ, Scholpp S, Brand M, et al. (2007) Early
developmental specification of the thyroid gland depends on han-expressing
surrounding tissue and on FGF signals. Development 134: 2871–2879.
28. Shen L, Li XF, Shen AD, Wang Q, Liu CX, et al. (2010) Transcription factor
HAND2 mutations in sporadic Chinese patients with congenital heart disease.
Chin Med J (Engl) 123: 1623–1627.
29. Strehle EM, Yu L, Rosenfeld JA, Donkervoort S, Zhou Y, et al. (2012)
Genotype-phenotype analysis of 4q deletion syndrome: proposal of a critical
region. Am J Med Genet A 158A: 2139–2151.
30. Tamura M, Hosoya M, Fujita M, Iida T, Amano T, et al. (2013) Overdosage of
Hand2 causes limb and heart defects in the human chromosomal disorder
partial trisomy distal 4q. Hum Mol Genet 22: 2471–2481.
31. Tumer Z, Bach-Holm D (2009) Axenfeld-Rieger syndrome and spectrum of
PITX2 and FOXC1 mutations. Eur J Hum Genet 17: 1527–1539.
32. Zidere V, Tsapakis EG, Huggon IC, Allan LD (2006) Right aortic arch in the
fetus. Ultrasound Obstet Gynecol. 28(7):876–81.
Cardiac Transcription Factor Variants in TOF
PLOS ONE | www.plosone.org 8 August 2014 | Volume 9 | Issue 8 | e95453
